Get the Stockscreener App
1.20
0.84%
0.01
After Hours:
1.20
In 8 Bio Inc stock is traded at $1.20, with a volume of 30,214.
It is up +0.84% in the last 24 hours and down -18.91% over the past month.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.
See More
Previous Close:
$1.19
Open:
$1.2
24h Volume:
30,214
Relative Volume:
0.53
Market Cap:
$11.51M
Revenue:
-
Net Income/Loss:
$-18.98M
P/E Ratio:
-0.4205
EPS:
-2.8535
Net Cash Flow:
$-14.55M
1W Performance:
-9.77%
1M Performance:
-18.91%
6M Performance:
-50.00%
1Y Performance:
-50.21%
1-Day Range:
$1.195
$1.2422
1-Week Range:
$1.19
$1.33
52-Week Range:
$1.17
$2.73
In 8 Bio Inc Stock (INAB) Company Profile
Name
In 8 Bio Inc
Sector
Industry
Phone
(646) 600-6438
Address
EMPIRE STATE BUILDING, NEW YORK
Compare INAB vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INAB
In 8 Bio Inc
|
1.20 | 11.41M | 0 | -18.98M | -14.55M | -2.8535 |
VRTX
Vertex Pharmaceuticals Inc
|
477.36 | 120.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
656.01 | 68.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
918.22 | 57.84B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.23 | 40.13B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
271.77 | 35.88B | 4.29B | 577.22M | 641.34M | 4.2086 |
In 8 Bio Inc Stock (INAB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-18-24 | Initiated | Laidlaw | Buy |
| Aug-30-22 | Initiated | H.C. Wainwright | Buy |
In 8 Bio Inc Stock (INAB) Latest News
Cabaletta Bio (CABA) sees Millennium group report 2.07M-share, 1.3% ownership stake - Stock Titan
Kala Bio, Inc. Files Form 8-K with SEC Detailing Nasdaq Listing and Corporate Information - Minichart
Nuvation Bio sets Aug. 6 webcast on cancer treatment updates - Stock Titan
Belite Bio (BLTE) Leerink’s Global Healthcare Conference 2025 Summary - Quartr
Nuvation Bio (NUVB) CFO exercises 40,000 share options and boosts holdings - Stock Titan
Valion Bio (OTC: VBIO) investor group caps ownership at 9.99% with blocker - Stock Titan
Leadership shake-up at Biorestorative Therapies (NASDAQ: BRTX) and new CEO - Stock Titan
Entera Bio (NASDAQ: ENTX) expands share authorization and equity plan pool - Stock Titan
Bio-Path Holdings (BPTH) plans AML trial restart and crypto treasury - Stock Titan
Q32 Bio Enters Underwriting for $18.25 Offering, Net Proceeds ~$188M; Option Lifts to ~$216M - TradingView
Q32 Bio (Nasdaq: QTTB) raises $187.6M in stock and pre-funded warrant deal - Stock Titan
Gossamer Bio (NASDAQ: GOSS) wins approval to boost authorized shares to 4.0B - Stock Titan
Valion Bio (OTC: VBIO) details biodefense and oncology plans - Stock Titan
Q32 Bio (QTTB) shows Phase 2a alopecia areata responses with bempikibart - Stock Titan
[8-K] Q32 Bio Inc. Reports Material Event - Stock Titan
Experimental alopecia areata drug sees 40% of patients hit key hair regrowth mark - Stock Titan
Can Nuvation Bio Inc (NUVB) Stock Soar 150% From Current Level? - Yahoo Finance
Gossamer Bio (GOSS) Proxy filing Summary - Quartr
Palisade Bio (PALI) director adds 45,000 shares through July open-market buys - Stock Titan
Q32 Bio to Report 36-Week Topline Results from Part B of SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata on July 13, 2026 - TradingView
symbol__ Stock Quote Price and Forecast - CNN
Annovis Reaches Full Enrollment in Phase 3 Buntanetap Trial, 850 Patients Enrolled - TradingView
Annovis Bio (NYSE: ANVS) completes enrollment in 850-patient Phase 3 Alzheimer’s study - Stock Titan
IN8bio Announces Publication in The Journal of Clinical Oncology Demonstrating DeltEx™ DRI Doubles Progression-Free Survival in Newly Diagnosed Glioblastoma - GlobeNewswire Inc.
Kevin Tang’s Tang Capital buys $141,864 in Boundless Bio (BOLD) By Investing.com - Investing.com India
Form 4 Boundless Bio Inc For: 8 July By Investing.com - Investing.com Canada
Ten percent owner of Boundless Bio (NASDAQ: BOLD) adds shares - Stock Titan
Form 4 Palisade Bio Inc For: 8 July By Investing.com - Investing.com Nigeria
The Longevity Protein Race Reaches Manufacturing: One Microcap Just Completed A GMP Master Cell Bank For Its Anti-Aging Klotho Therapy - Morningstar
BIO-key Regains Nasdaq Compliance; Trading to Resume July 8 - TradingView
Inmune Bio (NASDAQ: INMB) director exercises 14,801 warrants at $1.40 - Stock Titan
INmune Bio (INMB) CSO exercises April 2024 warrants and extends remaining term - Stock Titan
Inmune Bio (INMB) CEO exercises 9,014 April 2024 warrants at $1.40 - Stock Titan
Belite Bio to Participate in the Piper Sandler Virtual Ophthalmology Investor Symposium - GlobeNewswire
Passage BIO (NASDAQ: PASG) holder Lynx1 reports 21% ownership amid Remix deal - Stock Titan
Climb Bio, Inc. Files Form 8-K: Key Company Information, NASDAQ Listing, and Emerging Growth Status - Minichart
D.E. Shaw discloses 8.3% Gossamer Bio (GOSS) ownership stake - Stock Titan
Breanna O’Reilly joins Climb Bio (NASDAQ: CLYM) board with stock option grant - Stock Titan
Gossamer Bio (NASDAQ: GOSS) sets note conversion rate and warrant exercise price - Stock Titan
INmune Bio Inc. Announces Warrant Inducement Offer and Amendment to April 2024 Warrants – Key Details from Latest 8-K Filing – Minichart - Minichart
Inmune Bio Raises ~$0.9M Via $1.40 Warrant Inducement, Extends Remaining Warrants to 2027 - TradingView
INmune Bio (NASDAQ: INMB) cuts warrant price, extends 2027 expiry - Stock Titan
Avai Bio (AVAI) notifies SEC of late FY2026 10-K, cites financial compilation - Stock Titan
Tang-linked entities report 11.3% stake in Boundless Bio (NASDAQ: BOLD) - Stock Titan
Baselake Partners (PASG) reports 235,058 shares, 7.3% ownership - Stock Titan
CABA Forecast — Price Target — Prediction for 2027 - TradingView
INmune Bio clears key UK pediatric review for Ebstrocel in RDEB - Stock Titan
Passage Bio to Merge With Remix Therapeutics; Remix Valued at $226M, $100M Financing - TradingView
Remix Therapeutics to reverse-merge with Passage Bio (PASG) and raise $100M - Stock Titan
Passage Bio (PASG) to combine with Remix; Remix valued at $226M, $100M raise - Stock Titan
[144] Nuvation Bio Inc. SEC Filing - Stock Titan
In 8 Bio Inc Stock (INAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.46%
0.84%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):